Answers are grounded in this paper and cite their sources.
Real-life study shows mepolizumab reduces nasal polyp size and improves quality of life in patients with CRSwNP, suggesting potential benefits in standard care.
The results support the use of mepolizumab as an effective option in the current standard of care for patients affected by severe, uncontrolled CRSwNP especially in decreasing nasal polyps’ size and improving quality of life, although a minor impact was observed on recovery of smell.
No takes yet. Share an insight, caveat, or question.
Corso et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: